


Immuno-Oncology

JUNE 2, 2021



| Date | Time | Track | Presentation Title | Speaker |
|-------|------------------|--|--|---|
| 2-Jun | 06:00 - 07:00 AM | New Advancements in Immuno-Oncology | Dynamic live cell imaging of adherent and immune cells using CellASIC® ONIX2 microfluidic platform | Jun Park, PhD Senior Scientist, MilliporeSigma |
| 2-Jun | 06:00 - 07:00 AM | Emerging Targets for Immuno-Oncology Therapy | The Good, The Bad & The Ugly: Research solutions for key regulators of the tumor microenvironment | Josh Mahlios, Ph.D. Senior Marketing Product Manager, Miltenyi Biotec |
| 2-Jun | 07:30 - 08:30 AM | New Advancements in Immuno-Oncology | Industry Response to the Expanding Need in Immuno-Oncology for Validated Antibodies | Brian McWilliams, PhD IP/WB Manager at Fortis Life Sciences |
| 2-Jun | 07:30 - 08:30 AM | | Panel Presentation: xMAP® INTELLIFLEX and Immunoassay Innovations: Tools to advance immuno-oncology research | Sigrun Badrnya, PhD Manager Product Development, Life Sciences, Thermo Fisher Scientific Wilco de Jager, PhD Sr. Field Applications Scientist, Luminex |
| 2-Jun | 09:00 - 10:00 AM | New Advancements in Immuno-Oncology | Making sense out of multiplex | Dave Mason, PhD Technical Sales Specialist, Visiopharm |
| 2-Jun | 09:00 - 10:00 AM | Emerging Targets for Immuno-Oncology Therapy | Panel Presentation: Luminex Imaging and Flow Cytometry in Immuno-Oncology | Katie Gillis Product Manager, Microcapillary Flow Cytometry, Luminex Corporation Brian E. Hall Product Manager, Image Flow Cytometry, Luminex Corporation Stephanie Brunelle, Ph.D. Product Manager, CellStream, Luminex Corporation |

| | | | | |
|-------|---------------------------|---|--|--|
| 2-Jun | 10:30 - 11:30 AM | New Advancements in Immuno- Oncology | Keynote Presentation: New Checkpoints and Biomarkers | Gordon J. Freeman, PhD Professor of Medicine, Harvard Medical School |
| 2-Jun | 12:00 - 01:00 PM | New Advancements in Immuno- Oncology | Genetically-Engineered Immuno-oncology Cell Lines and Services for Early Drug Discovery Research and Preclinical Manufacturing | Stacey Ward, PhD R&D Manager, Advanced Genetic and Cell Technologies, MilliporeSigma |
| 2-Jun | 12:00 - 01:00 PM | Emerging Targets for Immuno- Oncology Therapy | Understand the resistance mechanisms of CAR T cell therapy | Yong Gu Lee Ph.D Assistant Professor, Hanyang University, College of Pharmacy |
| 2-Jun | 01:30 - 02:30 PM | Emerging Targets for Immuno- Oncology Therapy | Keynote Presentation: Hypoxia Drives Tumor Immune Suppression and Immunotherapy Resistance | Michael A. Curran, PhD Associate Professor of Immunology, MD Anderson Cancer Center, The University of Texas |
| 2-Jun | 03:00 - 04:00 PM | Emerging Targets for Immuno- Oncology Therapy | Discover the WOLF G2 Cell Sorter, the latest in Microfluidic Gentle Cell Sorting for Immuno-Oncology Applications | Lindsey Wolf Product Manager at NanoCollect Biomedical, inc. |
| 2-Jun | 03:00 - 04:00 PM | Emerging Targets for Immuno- Oncology Therapy | Functional Evaluation of Unique Anti-PDL1 Antibodies Generated through Single Plasma B Cell Cloning on the Beacon® Platform Versus a Standard Hybridoma Approach | Neha Yevalekar Scientist II |
| 2-Jun | 04:30 - 05:30 PM | New Advancements in Immuno- Oncology | Advances in High-Throughput Drug Screening Using TrueGel3D® HTS Hydrogel 3D Cell Culture Plates | Nick Asbrock, B.S. Global Product Manager for Stem Cell and 3D Cell Culture |
| 2-Jun | 04:30 - 05:30 PM | New Advancements in Immuno- Oncology | How to get all information from your tissue sample with less complexity: An introduction to automated Multiplexing IHC and Spatial genomic analysis | Sara Milosevic, Ph.D. Sales Specialist Europe, Lunaphore Technologies |
| 2-Jun | 12:00 - 12:45 AM | Emerging Targets for Immuno- Oncology Therapy | Development of FGFR4 targeted Chimeric Antigen Receptors (CARs) for treatment of Rhabdomyosarcoma | Peter Sullivan, PhD Postdoctoral Fellow, Laboratory of Dr. Rimas Orentas, Seattle Children's Research Institute |

| | | | | |
|-------|------------------|--|---|---|
| 2-Jun | 12:00 - 12:45 AM | New Advancements in Immuno-Oncology | Engineering universal chimeric antigen receptors (CARs) for cancer therapy | Jason Lohmueller, Ph.D. Assistant Professor, Departments of Surgery and Immunology, University of Pittsburgh, Division of Surgical Oncology Research, UPMC Hillman Cancer Center |
| 2-Jun | 12:00 - 12:45 AM | Emerging Targets for Immuno-Oncology Therapy | EZH2 as an Actionable Therapeutic Target to Enhance Anti-Tumor Immune Response In Prostate Cancer | Leigh Ellis, Ph.D. Acting Associate Professor of Medicine, Cedars-Sinai Medical Center |
| 2-Jun | 12:00 - 12:45 AM | Emerging Targets for Immuno-Oncology Therapy | Fueling Antitumor Immunity Using Oncolytic Viruses Encoding Metabolic Modulators | Dayana Rivadeneira, PhD Research Assistant Professor, Department of Immunology University of Pittsburgh |
| 2-Jun | 12:00 - 12:45 AM | Advancing Cancer Immunotherapies to the Clinic | IDO in Melanoma..... Deserves Further Evaluation | Yousef Zakharia, MD Associate Professor of Medicine, University of Iowa |
| 2-Jun | 12:00 - 12:45 AM | Emerging Targets for Immuno-Oncology Therapy | IFN γ -activated dermal lymphatic vessels restrict anti-tumor immunity | Amanda Lund, PhD Associate Professor, Ronald O. Perleman Department of Dermatology and Pathology; NYU Grossman School of Medicine Member, Laura and Isaac Perlmutter Cancer Center, NYU Langone Health |
| 2-Jun | 12:00 - 12:45 AM | Emerging Targets for Immuno-Oncology Therapy | Interrogating mechanisms of tumor-specific T cell exhaustion and activity in pancreatic ductal adenocarcinoma | Adam Burrack, M.S., Ph.D. Researcher, University of Minnesota, Center for Immunology |
| 2-Jun | 12:00 - 12:45 AM | New Advancements in Immuno-Oncology | Rational Modifications to CAR Antigen Binding Domain Improve Sensitivity to Low-Density Target Antigens | Kole DeGolier, B.S. PhD Candidate - Fry Lab Department of Immunology University of Colorado |
| 2-Jun | 12:00 - 12:45 AM | New Advancements in Immuno-Oncology | Th17-Inducing Vaccines for the Treatment of Ovarian Cancer | Keith Knutson, PhD Professor of Immunology, Mayo Clinic |
| 2-Jun | 12:00 - 12:45 AM | New Advancements in Immuno-Oncology | Using genetically engineered preclinical models to study T cell therapy against solid tumors | Leah Schmidt, PhD Postdoctoral Fellow, Fred Hutchinson Cancer Research Center |